Delving into the Latest Updates on Ipilimumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti CTLA-4 monoclonal antibody, Anti-CTLA-4 Mab, Ipilimumab (Genetical Recombination)

+ [17]

Target

CTLA4

Action

inhibitors

Mechanism

CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [11]

Active Indication

MSI-H/dMMR Rectal CancerPD-L1 positive Non-Small Cell Lung CancerMetastatic hepatocellular carcinoma+ [266]

Inactive Indication

Acute bilineal leukemiaAcute Biphenotypic LeukemiaAcute lymphoblastic leukemia recurrent+ [153]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

National Cancer Institute

Bristol Myers Squibb Co.

The University of Texas MD Anderson Cancer Center

+ [15]

Inactive Organization

National Institutes of Health Clinical Center

Personal Genome Diagnostics, Inc.

The University of Texas Southwestern Medical Center

+ [11]

License Organization

Nektar Therapeutics

Inspirna, Inc.

Nexoplex Bio, Inc.

+ [8]

Drug Highest PhaseApproved

First Approval Date

United States (25 Mar 2011),

Melanoma

RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Conditional marketing approval (China), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (Australia), Breakthrough Therapy (China), Priority Review (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 143797L

Source: *****

Sequence Code 9060585H

Source: *****

This is a phase 1, open-label, multicentric study evaluating the safety, feasibility and efficacy of ODI-2001, a personnalized therapeutic cancer vaccine composed of DNA neoantigen vaccine, Modified Vaccinia virus Ankara (MVA) viral adjuvant and anti-CTLA4 (ipilimumab), in patients with metastatic or locally advanced colorectal or pancreatic cancer. The study includes a dose-escalation phase to determine the maximum tolerated dose (MTD) followed by an expansion phase to evaluate efficacy in terms of progression-free survival

Start Date01 Nov 2026

Sponsor / Collaborator

Centre Georges François Leclerc

NCT07689175

/ Not yet recruitingPhase 2IIT

Phase 2 Trial of Adaptive Dosing of Immune Checkpoint Inhibitors for Unresectable Child Pugh B Hepatocellular Carcinoma

The goal of this clinical trial is to learn if immunotherapy including nivolumab plus ipilimumab is effective and safe in treating hepatocellular carcinoma.

Start Date31 Oct 2026

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

[+1]

NCT07511036

/ Not yet recruitingPhase 2IIT

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

This is a phase II study testing the safety and preliminary efficacy of triplet ICB in treatment naïve patients with clinical stage III or oligometastatic stage IV melanoma with resectable disease.

Start Date01 Sep 2026

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

100 Clinical Results associated with Ipilimumab

Login to view more data

100 Translational Medicine associated with Ipilimumab

Login to view more data

100 Patents (Medical) associated with Ipilimumab

Login to view more data

5,708

Literatures (Medical) associated with Ipilimumab

31 Dec 2026·CNS oncology

Tailored management of a melanoma patient with bleeding brain metastases and deep vein thrombosis with thrombectomy

Article

Author: Ceccarelli, Corrado ; Pastina, Ilaria ; Del Roscio, Davide ; De Angelis, Filippo ; Viterbo, Antonella ; Pieraccini, Massimo ; Arezzini, Luca

CASE PRESENTATION:

We describe a 62-year-old man with disseminated melanoma (initially staged pT2aN0M0, AJCC stage IB, 8th edition AJCC) who developed multiple brain metastases with hemorrhagic transformation, pulmonary embolism, retrobulbar progression with eyeball herniation, and deep vein thrombosis (DVT). After cerebral edema improved with corticosteroid tapering and the patient became asymptomatic, he started combination immunotherapy with ipilimumab (3 mg/kg q3w × 4) and nivolumab (1 mg/kg q3w × 4). Despite initial benefit, progression led to radiotherapy for retrobulbar lesion and subsequent targeted therapy with encorafenib (450 mg daily) and binimetinib (45 mg twice daily). Shortly after, the patient developed symptomatic left-leg DVT extending to the femoral vein with segmental pulmonary embolism. Given the contraindication to full anticoagulation, mechanical thrombectomy with the Indigo Aspiration System was performed, followed by prophylactic LMWH at reduced therapeutic dose (enoxaparin 1 mg/kg once daily due to recent thrombectomy and hemorrhagic risk from bleeding brain metastases). During targeted therapy, the patient experienced partial regression of brain, liver, and peritoneal metastases, although intracranial hemorrhage recurred later.

CONCLUSIONS:

This case highlights the value of a multidisciplinary, tailored approach integrating immunotherapy, radiotherapy, targeted therapy, and mechanical thrombectomy with no DVT recurrence observed following thrombectomy at 6-month follow-up.

01 Dec 2026·JOURNAL OF BIOMOLECULAR NMR

A fast and efficient strategy for the NMR assignment of Fab methyl groups

Article

Author: Henot, Faustine ; Doyen, Camille ; Frances, Oriane ; Güntert, Peter ; Vibert, Béatrice ; Crublet, Elodie ; Favier, Adrien ; Dbira, Sarra ; Giraud, Arthur ; Imbert, Lionel ; Boisbouvier, Jérôme ; Clavier, Séverine

Owing to their high specificity and therapeutic effectiveness, monoclonal antibodies (mAbs) have rapidly become one of the leading classes of biologic drugs used to treat critical illnesses. The antigen-binding fragment (Fab) of mAbs plays a key role in the antigen recognition, so its structural characterization is essential, as even a slight change to its Higher Order Structure (HOS) can impact the antibody's potency. Recently, 2D methyl NMR has been introduced as a powerful method to assess both the structure and integrity of therapeutic Fab fragments. However, the identification of methyl group resonances in NMR spectra remains rare since Fabs are large heterodimers of ~ 50 kDa. Here, we present the methyl group assignment of an IgG1 Fab produced in a cell-free system with an optimal isotope labelling. We first assigned 99% of the alanine, isoleucine, leucine, methionine, and valine methyl groups of the therapeutic Fab targeting LAMP1 antigen. Building on this assignment, we propose a "divide and conquer" strategy that exploits sequence identities to rapidly assign methyl groups of other IgG1 Fabs. We demonstrate that the assignment of the Fab's constant region can easily be transferred from one IgG1 to another and that the variable part of a new Fab can be assigned using smaller uniformly ¹⁵N,¹³C-labelled constructs. We applied our strategy to ipilimumab's Fab and, using the assignment of ipilimumab's variable part and Fab anti-LAMP1's constant part, we could transfer the assignment of 89% of the methyl-containing amino acids to the entire ipilimumab Fab without having to produce deuterated samples. This assignment strategy can be generalised to any other IgG1 Fabs provided that their constant regions are identical and the strategy can be adapted to accommodate the expression levels of the different variable domains. This new method drastically facilitates the Fab assignment process, making it suitable for the pharmaceutical timeline.

01 Aug 2026·SEMINARS IN ONCOLOGY

Risk of intensive care unit admission after immune checkpoint inhibitor use in cancer

Article

Author: Guarin, Geneva ; Bhandari, Sambhawana ; Baral, Maun R ; Ranganathan, Prabha ; McEvoy, Colleen ; Morgensztern, Daniel

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but can cause excessive immune activation, leading to severe adverse events, including intensive care unit (ICU) admission. Existing evidence on critical illness after ICI use is limited, largely single center, and focused on immune related adverse events. This study evaluates the risk of inpatient and ICU admissions after ICI initiation using two large national databases. We retrospectively analyzed MarketScan Commercial and Multi-state Medicaid Research Databases (2016-2022) to identify adults with solid organ malignancies treated with ICIs and determined if ICU admission was required within 90 days of ICI administration. The primary diagnosis for ICU admission was identified and categorized. Associations between cancer type, ICI type, and ICU admission were analyzed. About 33,040 patients received ICIs during the study period. About 48.9% were male and 51.1% female. Pembrolizumab was the most used (49.3%), followed by nivolumab (31.9%), and ipilimumab (9.4%). Lung cancer was the most common malignancy (40.8%), followed by genitourinary (16%), melanoma (13%), gastrointestinal (12%), and breast (10%). About 22.0% (n = 7,216) of patients were hospitalized, and 8.7% (n = 2,872) required ICU admission. Infection was the most frequent reason for ICU admission, followed by respiratory causes. The odds of being admitted to the ICU were higher with combination ICI (OR = 1.51, P < .001) compared to ICI monotherapy. In conclusion, among patients with solid organ malignancies, nearly 9% required ICU admission within 90 days of ICI initiation, most commonly for infectious causes. These findings highlight the need for heightened vigilance for critical illness in patients treated with ICIs.

1,001

News (Medical) associated with Ipilimumab

19 Jul 2026

·www.biospace.com

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose -- -- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 -- PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) were accepted for a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) Congress 2026, to be held October 23-27 in Madrid, Spain. Details of the Proffered Paper Oral Presentation ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Title: Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC) Presenter: Sumanta Pal, M.D., FASCO, Professor and Vice Chair of Academic Affairs, City of Hope Comprehensive Cancer Center ESMO has indicated that the abstract will be available on its website at 3:05 p.m. PDT on Sunday, October 18. XmAb819 Evaluation Across ENPP3+ Tumors XmAb819 is being evaluated for the treatment of patients with ENPP3+ tumors in a Phase 1 clinical study (Clinicaltrials.gov Identifier: NCT05433142). Initial results from dose-escalation in advanced ccRCC were presented during the AACR-NCI-EORTC Conference in October 2025. Currently: Expansion cohorts are evaluating intravenous doses to support selection of a dose for the planned Phase 3 pivotal study for patients with advanced ccRCC, Dose escalation of subcutaneous administration in advanced ccRCC is ongoing, A sub-study for patients with ENPP3+ advanced colorectal cancer, non-small cell lung cancer and papillary renal cell carcinoma opened to enrollment in the second quarter of 2026, and A sub-study for patients with intermediate- or poor-risk advanced ccRCC who have progressed after nivolumab in combination with ipilimumab as a first-line treatment (IO doublet therapy) is planned to open to enrollment in the third quarter of 2026. About XmAb819 XmAb819 is a first-in-class, tumor-targeted, T-cell engaging XmAb® 2+1 bispecific antibody in development for patients with clear cell renal cell carcinoma (ccRCC) and other tumors with high ENPP3 expression, including colorectal cancer, non-small cell lung cancer and papillary renal cell carcinoma. XmAb819 engages the immune system and activates T cells for highly potent and targeted lysis of tumor cells expressing ENPP3. ENPP3 is a differentially expressed target, with high-level expression in renal cell carcinoma (RCC) and low-level expression on normal tissues. With two tumor-antigen binding domains and one T-cell binding domain, Xencor’s XmAb® 2+1 format enables antibodies to bind more avidly and selectively kill tumor cells with higher antigen density, potentially sparing normal cells. About Xencor Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor’s XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit . Forward-Looking Statements Certain statements contained in this press release may constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by the use of words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “indicates,” “supports,” and similar terms, or by express or implied discussions relating to Xencor’s business, including, but not limited to, statements regarding the timing and content of a presentation on the results from a Phase 1 study of XmAb819 in advanced clear cell renal cell carcinoma, projected clinical study timelines, and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics, the ability of publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments, the risk of loss of key members of management, the risk that the fair value of our marketable equity securities will decline and the risks, uncertainties and other factors described under the heading “Risk Factors” in Xencor's Annual Report on Form 10-K for the year ended December 31, 2025 as well as Xencor's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Xencor undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. Contacts For Investors: Charles Liles cliles@xencor.com (626) 737-8118 For Media: Cassidy McClain Inizio Evoke cassidy.mcclain@inizioevoke.com (619) 694-6291

Phase 1AACRASCOImmunotherapy

15 Jul 2026

·allsci.com

Septa acquires CeeNU from BMS to end Canada’s critical chemotherapy shortage

Mississauga, Ontario-based Septa Pharmaceuticals has acquired CeeNU (lomustine) from Bristol Myers Squibb (NYSE: BMY) Canada, effective June 29, 2026, resolving a documented patient access crisis for a chemotherapy agent used in brain tumors and Hodgkin’s lymphoma that had been on Canada’s Tier 3 Drug Shortages List — the highest severity designation. The deal is not a conventional commercial transaction. BMS Canada filed a formal discontinuation notice with Health Canada in April 2024, triggering a supply gap that led to emergency importation of UK-labelled lomustine into British Columbia. No generic manufacturer stepped in despite the molecule being off-patent, leaving Septa to fill a structural market gap rather than pursue a standard specialty pharma acquisition. Lomustine is an alkylating agent in the nitrosourea class that crosslinks and damages DNA strands, inhibiting replication in rapidly dividing cancer cells. It remains a standard-of-care chemotherapy for recurrent glioblastoma and certain Hodgkin’s lymphoma regimens in Canada, with no approved targeted replacement in the recurrent glioblastoma setting. Active clinical trials continue to use it as a backbone or comparator, including a randomized Phase II trial at McGill evaluating eflornithine plus lomustine versus lomustine alone in approximately 280 patients. Financial terms were not disclosed. The absence of a headline price is consistent with the access-driven context of the deal and the modest commercial ceiling imposed by Canada’s Patented Medicine Prices Review Board, which limits the pricing upside available to Septa relative to what US acquirers have historically exercised on similar assets. The closest structural precedent is BMS’s divestiture of US lomustine rights to NextSource Biotechnology in 2013, which led to the rebranded Gleostine and a subsequent price increase of approximately 1,400% — a strategy structurally unavailable to Septa under Canadian price controls. The Canada transaction appears to complete BMS’s global exit from lomustine, a molecule the company originally developed and commercialized, consistent with its decade-long strategy of divesting off-patent chemotherapy assets to concentrate capital on immuno-oncology, cell therapy, and novel mechanisms. BMS has simultaneously been expanding its Canadian oncology presence through novel approvals, including Health Canada clearances for Breyanzi (lisocabtagene maraleucel) in second-line diffuse large B-cell lymphoma and dual immunotherapy Opdivo (nivolumab) plus Yervoy (ipilimumab) for colorectal and liver cancers. For Septa, the CeeNU acquisition represents a foundational oncology asset and establishes the company as a supply-critical provider in the Canadian market — a positioning that may facilitate future acquisitions of similarly distressed or divested oncology brands from large pharma. The company has indicated it is actively seeking further in-licensing and out-licensing opportunities globally. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

ImmunotherapyPhase 2AcquisitionDrug ApprovalCell Therapy

15 Jul 2026

·allsci.com

Kelun-Biotech’s sac-TMT meets Phase III endpoint in first-line PD-L1-negative NSCLC

Sichuan Kelun-Biotech Biopharmaceutical (HKEX: 6990.HK) has reported that its Phase III OptiTROP-Lung06 trial of sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) plus Merck’s Keytruda (pembrolizumab) met its primary endpoint of progression-free survival in first-line PD-L1-negative non-squamous non-small cell lung cancer — a population where immunotherapy alone offers limited benefit and platinum-based chemotherapy remains the backbone of treatment. The result extends the clinical case for sac-TMT beyond PD-L1-positive disease. In the companion OptiTROP-Lung05 study, sac-TMT plus pembrolizumab previously demonstrated superiority over pembrolizumab monotherapy in PD-L1-positive NSCLC, with those findings presented at ASCO 2026 and published in The Lancet. Together, the two trials position sac-TMT as a potential first-line option across the full spectrum of PD-L1 expression in driver gene-negative non-squamous NSCLC. The findings also strengthen the clinical foundation for Merck’s global development program for sac-TMT, which the company licensed outside Greater China in 2022. Sac-TMT is a TROP2-directed antibody-drug conjugate that delivers a belotecan-derived topoisomerase I inhibitor payload intracellularly, inducing DNA damage and apoptosis in tumor cells while enabling bystander killing of adjacent cells through membrane-permeable payload release. The combination with pembrolizumab, which blocks the PD-1 checkpoint to restore T-cell-mediated tumor killing, is designed to exploit synergistic immune and cytotoxic mechanisms — potentially overcoming the limited immunotherapy response seen in PD-L1-low or -negative tumors. OptiTROP-Lung06 is a randomized, open-label, multicenter Phase III trial comparing sac-TMT plus pembrolizumab against pembrolizumab plus pemetrexed and platinum-based chemotherapy. At a pre-specified interim analysis, the combination demonstrated a statistically significant and clinically meaningful PFS improvement, with a positive OS trend also observed. The safety profile was consistent with prior studies, with no new signals identified. Specific numerical data — median PFS, hazard ratios, and p-values — were not disclosed in the announcement. Kelun-Biotech plans to engage China’s Center for Drug Evaluation based on these results. Sac-TMT already holds four approved indications in China, including previously treated EGFR-mutant non-squamous NSCLC and triple-negative breast cancer, and is the world’s first TROP2-directed ADC approved for lung cancer. A new indication application for first-line PD-L1-positive NSCLC based on the Lung05 study is under priority review at China’s NMPA. The Lung06 results could support an additional regulatory submission seeking to expand use into the PD-L1-negative first-line setting. Merck holds exclusive rights to develop and commercialize sac-TMT outside Greater China and has 17 ongoing global Phase III studies evaluating the molecule. The PD-L1-negative first-line setting is currently treated with pembrolizumab plus pemetrexed and platinum chemotherapy — the regimen against which Lung06 was evaluated — alongside atezolizumab-based regimens and dual checkpoint combinations such as nivolumab plus ipilimumab. These approaches rely on chemotherapy or dual immunotherapy to achieve meaningful benefit in this population. If confirmed in full data presentation, an ADC-plus-checkpoint regimen capable of replacing cytotoxic chemotherapy could represent a meaningful shift in first-line treatment, although cross-trial comparisons remain limited until detailed results are presented and peer-reviewed. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Phase 3ImmunotherapyClinical ResultLicense out/inPriority Review

100 Deals associated with Ipilimumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04603	Ipilimumab	L01XC11	DB06186

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
MSI-H/dMMR Rectal Cancer	Japan	Bristol-Myers Squibb KK	25 Aug 2025
PD-L1 positive Non-Small Cell Lung Cancer	China	Bristol-Myers Squibb Pharma EEIG	22 Jul 2025
Metastatic hepatocellular carcinoma	Australia	Bristol-Myers Squibb Australia Pty Ltd.	27 Jun 2025
Advanced Hepatocellular Carcinoma	European Union	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Iceland	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Liechtenstein	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Norway	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	European Union	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Iceland	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Liechtenstein	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Norway	Bristol Myers Squibb Co.	08 Mar 2025
Mismatch repair-deficient Colonic Cancer	European Union	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Iceland	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Mismatch repair-deficient Colonic Cancer	Norway	Bristol-Myers Squibb Pharma EEIG	13 Jan 2025
Unresectable Esophageal Squamous Cell Carcinoma	United States	Bristol Myers Squibb Co.	27 May 2022
Esophageal Carcinoma	Japan	Bristol-Myers Squibb KK	26 May 2022
Hepatocellular Carcinoma	United States	Bristol Myers Squibb Co.	10 Mar 2020
Melanoma, Cutaneous Malignant	United States	Bristol Myers Squibb Co.	10 Jul 2018
Colorectal Cancer	United States	Bristol Myers Squibb Co.	16 Apr 2018

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Phase 3	United States	Ono Pharmaceutical Co., Ltd.	30 Jan 2022
HER2 negative Gastric Cancer	Phase 3	Japan	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
HER2 negative Gastric Cancer	Phase 3	South Korea	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
HER2 negative Gastric Cancer	Phase 3	Taiwan Province	Ono Pharmaceutical Co., Ltd.	05 Nov 2021
Glioblastoma	Phase 3	United States	National Cancer Institute	01 Sep 2020
Gliosarcoma	Phase 3	United States	National Cancer Institute	01 Sep 2020
Non-small cell lung cancer stage III	Phase 3	Netherlands	Bristol Myers Squibb Co.	16 Dec 2019
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	United States	Bristol Myers Squibb Co.	08 Oct 2019
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Bristol Myers Squibb Co.	08 Oct 2019
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Japan	Bristol Myers Squibb Co.	08 Oct 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03682276 (PRIME-HCC, CTgov)	Phase 1/2	Hepatocellular Carcinoma	33	Ipilimumab+Nivolumab	zgqncvwekp = viqzlmzoux cjdcxwdche (ctykdadptc, tuwnfqiopj - oxfcoupkaq) View more	-	29 Jun 2026
NCT03958383 (CTgov)	Phase 1/2	Melanoma	8	hu14.18-IL2 fusion protein (Phase IA)	cjtbceuiaj = sndvuqpsqx ixdsblopaf (uwwzvlatrx, hcqbkirodi - fogngojygm) View more	-	03 Jun 2026
				hu14.18-IL2 (Phase IB)	cjtbceuiaj = guebqsmisr ixdsblopaf (uwwzvlatrx, xjntegdcan - bdbxraokfh) View more
NCT05665348 (PRODIGE 81-FFCD 2101-TRIPLET HCC, Pubmed \| Lancet Gastroenterol Hepatol)	Phase 2/3	Advanced Hepatocellular Carcinoma First line	226	Atezolizumab + Bevacizumab + Ipilimumab	gfknrwxlkd(knbiwmqexd) = 3% of patients in the atezolizumab plus bevacizumab group experienced acute renal failure jwjldygvks (ixoyxhzfxr ) View more	Negative	01 Jun 2026
				Atezolizumab + Bevacizumab
NCT06712927 (RELATIVITY-048, ASCO2026)	Phase 2	Melanoma	60	Nivolumab 480mg + Relatlimab 160mg IV Q4W + Ipilimumab 1mg/kg IV Q8W	frdmceqrks(fdgmsblgrw) = duowyxsask hbygsrejlh (txbabdtsap ) View more	Positive	29 May 2026
				Nivolumab 480mg + Relatlimab 160mg IV Q4W + Ipilimumab 1mg/kg IV Q8W	frdmceqrks(fdgmsblgrw) = vlqatyyjgs hbygsrejlh (txbabdtsap )
ASCO2026	Not Applicable	Melanoma 2-hydroxybutyric acid	36	ipilimumab-nivolumab	cyeemssdyl(wxuavlgaew) = lnisabruzt irkebnyhxt (cmmlsdhshh ) View more	Positive	29 May 2026
ASCO2026	Not Applicable	BRAF V600E Mutation-Positive Melanoma Second line BRAF V600-mutant	63	Ipilimumab plus Nivolumab	ulbxwqsfkp(ilweiybkej) = ivudngiywp isnkhpmjya (vpcrejlmty ) View more	Negative	29 May 2026
				Anti-PD-1 monotherapy	ulbxwqsfkp(ilweiybkej) = gxhpqfmxja isnkhpmjya (vpcrejlmty ) View more
ASCO2026	Not Applicable	metastatic non-small cell lung cancer First line	344	Ipilimumab and Nivolumab	mdeqyfepgt(ovblkammez) = bgdzqiwjll pmsdqkfapb (hkudtdnxlz ) View more	Positive	29 May 2026
				Chemotherapy+PD-1/PD-L1 inhibitor	mdeqyfepgt(ovblkammez) = ywmyddejgx pmsdqkfapb (hkudtdnxlz ) View more
NCT02866383 (CheckPAC, ASCO2026)	Phase 2	Biliary Tract Neoplasms NordicPRO-C3 \| NordicC4G	61	nivolumab + nivolumab	oxykggxprs(jptlltmikw) = iglifnlbac btpztppher (eotfpiwzls ) View more	Positive	29 May 2026
				nivolumabipilimumab + nivolumabipilimumab + nivolumabipilimumab	qznpekvbko(rqcftsumil) = exlbgurxmj uderrvjbds (cpgqjghftt )
ASCO2026	Not Applicable	Renal Cell Carcinoma First line	2,760	Immune checkpoint inhibitors (BMI ≥25 kg/m2)	lfgenrlcyn(ebctuvtyfj) = Rates of emergency department visits, hospitalizations, and ICU admissions were similar between groups at both 1 and 3 years. sooebcngpr (mhojjxyrgk ) View more	Positive	29 May 2026
				Immune checkpoint inhibitors (BMI 18.5- < 25 kg/m2)
ASCO2026	Not Applicable	-	637	Ipilimumab/nivolumab	phunluohck(fxddscrzqd) = biiplsisux iwqjghurve (urqmrxqrcx ) View more	Negative	29 May 2026
				immune checkpoint inhibitor + tyrosine kinase inhibitor	phunluohck(fxddscrzqd) = zbtnamhurt iwqjghurve (urqmrxqrcx ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Ipilimumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation